Author

Jon M. Tinsley

Observed name: Jon Tinsley

Institution: Sarepta Therapeutics (United States)

Observed institutions: John Radcliffe Hospital, Oxagen (United Kingdom), Summit (United Kingdom), Sarepta Therapeutics (United States)

OpenAlex ID: A5108111943

Positional cloning of a novel gene influencing asthma from Chromosome 2q14

2003 · Maxine Allen, Andrea Heinzmann, et al. · Nature Genetics · 328

Iminosugars past, present and future: medicines for tomorrow

2010 · Graeme Horne, Francis X. Wilson, et al. · Drug Discovery Today · 326

Second-generation compound for the modulation of utrophin in the therapy of DMD

2015 · Simon Guiraud, Sarah E. Squire, et al. · Human Molecular Genetics · 89

PDF

Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification

2017 · Kristin Wilson, Crystal Faelan, et al. · Toxicologic Pathology · 72

PDF

Safety, tolerability, and pharmacokinetics of SMT C1100, a 2‐arylbenzoxazole utrophin modulator, following single‐ and multiple‐dose administration to healthy male adult volunteers

2015 · Jon Tinsley, Neil Robinson, et al. · The Journal of Clinical Pharmacology · 51

PDF

Automated Large-Scale Culture and Medium-Throughput Chemical Screen for Modulators of Proliferation and Viability of Human Induced Pluripotent Stem Cell–Derived Neuroepithelial-like Stem Cells

2012 · Donna McLaren, Thorsten Gorba, et al. · SLAS DISCOVERY · 47

PDF

Tau Pathology is PresentIn Vivoand DevelopsIn Vitroin Sensory Neurons from Human P301S Tau Transgenic Mice: A System for Screening Drugs against Tauopathies

2013 · Manuela Mellone, Dimitra Kestoras, et al. · Journal of Neuroscience · 44

PDF

Imaging-based chemical screens using normal and glioma-derived neural stem cells

2010 · Davide Danovi, Anna Falk, et al. · Biochemical Society Transactions · 28

226th ENMC International Workshop:

2017 · Annemieke Aartsma-Rus, Alessandra Ferlini, et al. · Neuromuscular Disorders · 14

Calmodulin regulation of utrophin actin binding

1995 · Steven J. Winder, Lance Hemmings, et al. · Biochemical Society Transactions · 11

227th ENMC International Workshop:

2017 · Raffaella Willmann, Filippo Buccella, et al. · Neuromuscular Disorders · 5

Future Clinical And Biomarker Development For SMT C1100, The First Utrophin Modulator To Enter Clinical Trials For Duchenne Muscular Dystrophy (DMD) (S6.004)

2014 · Jon Tinsley, Neil Robinson, et al. · Neurology · 4

eP213: Phase 2 multiple ascending-dose study of SRP-5051 PPMO in patients with DMD amenable to exon 51 skipping: Part A results

2022 · Craig Campbell, Katherine Mathews, et al. · Genetics in Medicine · 3

PDF

Utrophin modulators to treat Duchenne muscular dystrophy (DMD): Phase 1b Clinical Trial Results of SMT C1100 (P2.006)

2015 · Jon Tinsley, Francesco Muntoni, et al. · Neurology · 1

Zebrafish as a Model Vertebrate for Cardiotoxicity

2007 · Adrian Hill, Stephanie Albert, et al. · Journal of Pharmacological and Toxicological Methods · 1

P3‐330: Reducing tau phosphorylation through inhibition of O‐GlcNAc processing

2012 · Graeme Horne, Jon Tinsley, et al. · Alzheimer s & Dementia

P3‐169: Reduction of Tau phosphorylation via novel OGA inhibitors

2011 · Graeme Horne, Sihong Chen, et al. · Alzheimer s & Dementia

TREAT-NMD Activity A07: Accelerate preclinical phase of new therapeutic treatment development Work package 7.4: Develop standardised protocols and procedures for harmonising and accelerating pre-clinical studies (including standardised data analysis)

2009 · Sop Title, Annamaria De Luca, et al.

Works count: 18

Citation count: 1,024

H-index: 10

I10-index: 10